Mounjaro cost guide · 2026 prices · Updated 11 May 2026
Mounjaro Cost Australia 2026: Tirzepatide Price, Eligibility, vs Wegovy
Mounjaro (tirzepatide) is the newer-generation dual-agonist weight-loss medication from Eli Lilly. SURMOUNT-1 trial 2023 published the strongest weight-loss outcomes ever for a pharmacological agent (~21% body weight at 72 weeks). Available in Australia since 2024. Not on the PBS for weight loss. Same private price as Wegovy ($330-$450/month) but typically stronger efficacy. This guide covers cost, dosing, eligibility, side effects, and how Mounjaro compares to alternatives.
★Key takeaways
- ✓Mounjaro is NOT on the PBS for weight loss. Private price: $330-$450/month telehealth, $250-$380/month via your own GP.
- ✓Strongest published weight-loss outcomes of any GLP-1: ~21% body weight loss at 72 weeks (SURMOUNT-1 trial, 15mg dose).
- ✓Dual-agonist (GLP-1 + GIP) — stronger mechanism than Wegovy (GLP-1 only). Newer drug with less long-term data.
- ✓TGA-registered for BMI 30+ or BMI 27+ with weight-related comorbidity. Same BMI criteria as Wegovy.
- ✓6 dose strengths (2.5mg to 15mg). Standard escalation: 4 weeks per dose. Many patients maintain at 10mg-12.5mg long-term.
| Provider ⇅ | Monthly cost ⇅ | Includes ⇅ | Eligibility ⇅ | Notes ⇅ |
|---|---|---|---|---|
| Telehealth subscription (Pilot / Juniper / Mosh) | $330-$450/month | Consult + script + admin + shipping | BMI 30+ or 27+ comorbidity | Fastest onboarding |
| In-person medical weight-loss clinic | $280-$400/month + program fee | Comprehensive metabolic work-up | Same BMI criteria | Best for comorbidities |
| Your own GP + pharmacy | $250-$380/month script | + GP consultation (Medicare-rebated) | GP willing to prescribe | Cheapest ongoing care |
Mounjaro is NOT on the PBS for weight loss. All pathways are private price. Your own GP is the cheapest ongoing pathway if they're willing to prescribe.
| Provider ⇅ | Dose ⇅ | Stage ⇅ | Notes ⇅ |
|---|---|---|---|
| Week 1-4 | 2.5mg/week | Initiation | Tolerance establishment |
| Week 5-8 | 5mg/week | Early effect | Standard maintenance for some |
| Week 9-12 | 7.5mg/week | Progressive weight loss | Optional escalation |
| Week 13-16 | 10mg/week | Stronger effect | Common maintenance |
| Week 17-20 | 12.5mg/week | Near-maximum | Higher-target patients |
| Week 21+ | 15mg/week | Maximum dose | SURMOUNT-1 highest-loss group |
Standard titration: 4 weeks per dose step. Many patients reach effective dose at 7.5mg-10mg and maintain there. Higher doses (12.5-15mg) for maximum-weight-loss target; require longer titration and more side-effect tolerance.
Why Mounjaro is now the preferred GLP-1 for many prescribers
Mounjaro is the newer-generation weight-loss medication: a dual-agonist activating both GLP-1 (glucagon-like peptide-1) AND GIP (gastric inhibitory polypeptide) receptors. The dual mechanism produces stronger appetite suppression + glucose regulation than single-agonist GLP-1s like semaglutide.
SURMOUNT-1 trial published 2023: tirzepatide produced ~21% mean body weight loss at 72 weeks (15mg dose) vs placebo 3%. STEP-1 trial for Wegovy (same trial design): ~15% body weight loss. Mounjaro produced ~40% higher weight loss in head-to-head comparison.
SURMOUNT-2 (T2D patients): ~14% body weight loss. SURMOUNT-4 (maintenance trial after weight loss): maintained loss while on medication; weight regain on stopping similar to Wegovy.
PBS status (and why Mounjaro isn't subsidised for weight loss)
As at January 2026, Mounjaro is NOT on the PBS for weight loss. The PBS subsidises some glucose-lowering medications for type 2 diabetes but does not currently subsidise tirzepatide for weight-loss indications. PBAC submissions continue; cost-effectiveness analysis is the major hurdle.
Patients should plan for indefinite private cost ($3,500-$5,400/year). If PBS listing happens in future, it would likely be restricted to higher-BMI patients (40+) with specific comorbidities.
Mounjaro vs Wegovy: which to choose
Choose Mounjaro if: Maximum weight-loss is the priority. You're willing to accept slightly more GI side effects in some studies. You want the newest evidence-based option.
Choose Wegovy if: Longer clinical track record matters to you. You have cardiovascular disease (SELECT trial showed 20% MACE reduction). Your prescriber is more familiar with semaglutide dosing protocols.
Cost is identical ($330-$450/month). Most telehealth platforms offer both — your prescriber can advise based on your specific situation. Many patients try one for 6 months, switch to the other if response is inadequate.
Common questions
How much does Mounjaro cost in Australia in 2026?
Mounjaro is NOT on the PBS for weight loss. Private cost: $330-$450/month via telehealth subscription, or $250-$380/month script via your own GP + pharmacy + Medicare-rebated consultations. Annual cost: ~$3,500-$5,400. Same price as Wegovy. Mounjaro has slightly stronger weight-loss outcomes (~21% at maximum dose vs Wegovy ~15%) which is driving many new patients to choose it.
What's the difference between Mounjaro and Wegovy?
Mounjaro is a DUAL-agonist — activates both GLP-1 receptors AND GIP (gastric inhibitory polypeptide) receptors. Wegovy is a single GLP-1 agonist. The dual mechanism produces stronger weight-loss outcomes: SURMOUNT-1 trial showed ~21% body weight loss at 72 weeks (15mg dose) vs STEP-1 Wegovy ~15%. Side-effect profile similar (nausea, GI). Both are subcutaneous weekly injections. Same cost.
Am I eligible for Mounjaro?
TGA-registered eligibility: BMI 30+ kg/m² (Class I obesity or above), OR BMI 27-29.9 with at least one weight-related comorbidity (hypertension, dyslipidaemia, type 2 diabetes, sleep apnoea, cardiovascular disease, fatty liver). Telehealth platforms apply these criteria strictly; in-person clinics may extend to BMI 25+ with multiple comorbidities at clinical discretion.
Is Mounjaro on the PBS in Australia?
No — not for weight loss as at January 2026. Mounjaro is approved by the TGA for type 2 diabetes treatment (Mounjaro for T2D was the first indication, approved 2023). PBS listing for T2D indication is pending or partial; PBS listing for weight-loss is not on the current consideration list. Patients pay full private price.
How much weight will I lose on Mounjaro?
SURMOUNT-1 trial (highest published outcomes for any GLP-1): 21% mean body weight loss at 72 weeks (15mg dose). 85% of patients lost 10%+ of body weight; 50% lost 20%+. SURMOUNT-2 (T2D patients): ~14% body weight loss. Individual response varies; 5-15% are non-responders (lose <5%, consider switch to surgery).
How does Mounjaro dose differ from Wegovy?
Mounjaro has 6 dose strengths (2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg) — more granular titration than Wegovy (5 doses). Standard escalation: 4 weeks per dose step. Many patients maintain at 10mg or 12.5mg rather than maximum 15mg. Highest dose achieves best weight loss; lower doses are reasonable maintenance with better tolerance.
What are the side effects?
Most common in first 4-8 weeks during titration: nausea (40-60%), constipation, diarrhoea, fatigue, decreased appetite. Slightly higher GI symptom rate than Wegovy in some studies. Less common: gallstones (with rapid weight loss), pancreatitis (rare), gastroparesis. Theoretical medullary thyroid cancer warning from rodent data — human data has not shown elevated risk.
Should I choose Mounjaro or Wegovy?
Mounjaro: stronger weight-loss outcomes (~21% vs 15%), newer with less long-term data, more dose granularity. Wegovy: longer clinical track record (since 2021), strong cardiovascular outcomes data (SELECT trial), broader prescriber familiarity. For maximum weight loss as priority: Mounjaro. For longest established track record: Wegovy. Cost identical. Many telehealth platforms now offer both — talk to your prescriber about which fits your situation.
How long do I need to take Mounjaro?
Indefinitely or until you transition to bariatric surgery. ~2/3 of weight lost is regained within 12 months of stopping without intensive lifestyle change. Treatment is chronic, like blood pressure medication. Some patients reduce dose over time (e.g. 12.5mg → 5mg maintenance) — this risks gradual weight regain.
Is Mounjaro safe for older adults?
Generally yes if they meet eligibility criteria. Caution: elderly with gastroparesis history, severe heart failure, kidney disease, or significant nutritional concerns. Always under GP supervision with regular monitoring. For frail elderly + weight loss, dietitian + behavioural support often preferred.
Next step
Use our BMI + pathway calculator to check Mounjaro eligibility, then browse telehealth providers or in-person clinics.